with robust revenue growth driven by increased surgeon adoption and procedural innovations. The company raised its adjusted EBITDA guidance and reaffirmed its cash flow positivity goals for the year.

A federal judge has denied the SEC and Ripple Labs' settlement bid due to procedural errors, despite both parties dropping ...